

BIOENVISION INC
Form SC 13D/A
August 02, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)*

BIOENVISION, INC.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

09059N100

(CUSIP Number)

Peter Wirth

Genzyme Corporation

500 Kendall Street

Cambridge, Massachusetts 02142

(617) 252-7500

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

with copies to:

Paul Kinsella

Ropes & Gray LLP

Edgar Filing: BIOENVISION INC - Form SC 13D/A

One International Place

Boston, Massachusetts 02110

(617) 951-7000

July 13, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: BIOENVISION INC - Form SC 13D/A

CUSIP No. 09059N100

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)

Genzyme Corporation
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)
06-1047163
2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/>
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization
Massachusetts

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

- | | |
|-----|--|
| 7. | Sole Voting Power |
| 8. | Shared Voting Power
18,031,682 (1) |
| 9. | Sole Dispositive Power |
| 10. | Shared Dispositive Power
18,031,682 (1) |

11. Aggregate Amount Beneficially Owned by Each Reporting Person
18,031,682 (1)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row (11)
27.9 %
14. Type of Reporting Person (See Instructions)
CO
(1) Assumes (i) full conversion of 2,250,000 shares of Series A Convertible Participating Preferred Stock into 4,500,000 shares of Common Stock and (ii) exercise of all 5,058,575 options to purchase Common Stock and 75,009 warrants to purchase Common Stock covered by Tender and Voting Agreements.

CUSIP No. 09059N100

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)

Wichita Bio Corporation
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)
41-2241310
2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/>
3. SEC Use Only
4. Source of Funds (See Instructions)
AF
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization
Delaware

- | | | | |
|---|-----|--|--|
| | 7. | Sole Voting Power | |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 8. | Shared Voting Power
18,031,682 (1) | |
| | 9. | Sole Dispositive Power | |
| | 10. | Shared Dispositive Power
18,031,682 (1) | |
| | 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
18,031,682 (1) | |
| | 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/> | |
| | 13. | Percent of Class Represented by Amount in Row (11)
27.9 % | |
| | 14. | Type of Reporting Person (See Instructions)
CO
(1) Assumes (i) full conversion of 2,250,000 shares of Series A Convertible Participating Preferred Stock into 4,500,000 shares of Common Stock and (ii) exercise of all 5,058,575 options to purchase Common Stock and 75,009 warrants to purchase Common Stock covered by Tender and Voting Agreements. | |

EXPLANATORY NOTE

This Amendment No. 5 (the Amendment) amends and supplements the statement on Schedule 13D originally filed by the Reporting Persons with the Securities and Exchange Commission (the SEC) on June 8, 2007 (as previously amended and supplemented, the Schedule 13D). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration

The second paragraph of Item 3, as amended, of the Schedule 13D is hereby deleted and replaced with the following:

The Offer expired at 12:01 a.m. (New York City time) on July 10, 2007. On July 10, 2007, Wichita Bio accepted for payment 8,398,098 Common Shares and 2,250,000 Preferred Shares that had been tendered and not withdrawn from the Offer, representing a total of 15.3% of the 55,035,740 outstanding Common Shares as of June 27, 2007 and 100% of the outstanding Preferred Shares as of June 27, 2007. Included in these figures are all Common Shares tendered by notice of guaranteed delivery that were validly delivered within three NASDAQ Global Market trading days after the July 10, 2007 expiration date of the Offer, as required by the terms of the notice of guaranteed delivery. Genzyme provided all funding required by Wichita Bio in connection with the acceptance for payment of the Common and Preferred Shares on July 10, 2007 from cash on hand.

Item 4. Purpose of Transaction

The second paragraph of Item 4, as amended, of the Schedule 13D is hereby deleted and replaced with the following:

The purpose of entering into the Merger Agreement and the Tender and Voting Agreements, and the purpose of the Offer, was to enable the Reporting Persons to acquire control of, and ultimately the entire equity interest in, Bioenvision. On July 2, 2007, pursuant to the Merger Agreement, the Reporting Persons (a) waived the condition that there be validly tendered and not withdrawn prior to the Expiration Date that number of Common Shares which represents a majority of the issued and outstanding Common Shares (assuming, for purposes of such calculation, the exercise or conversion of all vested in the money options and in the money warrants) and (b) extended the Expiration Date until 12:01 a.m., New York City time, on July 10, 2007. As of 12:01 a.m., New York City time, on July 10, 2007, a total of 8,398,098 Common Shares and 2,250,000 Preferred Shares were validly tendered and not withdrawn, representing approximately 15.3% of the 55,035,740 outstanding Common Shares and 100% of the outstanding Preferred Shares, both as of June 27, 2007.

Item 5. Interest in Securities of the Issuer

Subparagraphs (a) and (b) of Item 5, as amended, of the Schedule 13D are hereby deleted and replaced with the following:

a) As of the date hereof, the Reporting Persons own 8,398,098 Common Shares (representing 15.3% of the 55,035,740 outstanding Common Shares as of June 27, 2007) and 2,250,000 Preferred Shares (representing 100% of the outstanding Preferred Shares as of June 27, 2007). Additionally, for purposes of Rule 13d-3 under the Exchange Act, as a result of entering into the Tender and Voting Agreements, the Reporting Persons may also be deemed to possess beneficial ownership of the Stockholders Options and Warrants (5,058,575 options to purchase Common Stock and 75,009 warrants to purchase Common Stock). Therefore, the Reporting Persons may be deemed to beneficially own an aggregate of 18,031,682 Common Shares, representing approximately 27.9% of the fully diluted outstanding shares (assuming exercise of Stockholders Options and Warrants and conversion of the Preferred Shares with no accrued but unpaid dividends). The Reporting Persons and the other persons listed on Schedule I hereto, however, disclaim beneficial ownership of the Stockholders Options and Warrants, and this statement shall not be construed as an admission the Reporting Persons or those listed on Schedule I hereto is the beneficial owner for any purpose of the Stockholders Options and Warrants.

Except as set forth in this Schedule 13D, to the best of Genzyme's knowledge as of the date hereof, neither Genzyme nor any of its directors and executive officers named in Schedule I hereto owns any Bioenvision Shares. Except as set forth in this Schedule 13D, to the best of Wichita Bio's knowledge as of the date hereof, neither Wichita Bio nor any of its directors and executive officers named in Schedule I hereto owns any Bioenvision Shares.

b) As of the date hereof, the Reporting Persons have acquired the sole power to vote or direct the vote and to dispose or direct the disposition of 8,398,098 Common Shares and 2,250,000 Preferred Shares. For purposes of Rule 13d-3 under the Exchange Act, as a result of entering into the Tender and Voting Agreements, the Reporting Persons may also be deemed to have acquired the shared power to vote or direct the vote and to dispose or to direct the disposition of the Common Shares underlying the Stockholders Options and Warrants. Therefore, the Reporting Persons may be deemed to have acquired the shared power to vote or direct the

Edgar Filing: BIOENVISION INC - Form SC 13D/A

vote and to dispose or to direct the disposition of an aggregate of 18,031,682 Common Shares, representing approximately 27.9% of the fully diluted outstanding shares (assuming exercise of Stockholders' Options and Warrants and conversion of the Preferred Shares with no accrued but unpaid dividends).

4

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 2, 2007

GENZYME CORPORATION

By: /s/ Earl M. Collier, Jr.
Name: Earl M. Collier, Jr.
Title: Executive Vice President

WICHITA BIO CORPORATION

By: /s/ Earl M. Collier, Jr.
Name: Earl M. Collier, Jr.
Title: President